/ Published in SPOTLIGHTS

Adocia to Present four abstracts at ATTD 2019 in Berlin, Germany next February 20-23, 2019

Adocia to Present New Clinical Data on BioChaperone® Technology at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

Advanced Technologies & Treatments for Diabetes (ATTD 2019)

“The data presentations at the ATTD Annual Meeting demonstrate the potential of our BioChaperone technology to improve diabetes care and management,” commented Dr. Olivier Soula, Deputy General Manager at Adocia. “Specifically, BioChaperone Lispro showed a PK/PD profile at least equivalent to faster insulin aspart, the only approved ultra-rapid insulin and the first results obtained with BioChaperone Pramlintide Insulin, the first combination of its kind tested in clinics, encourage us to rapidly develop this combination of two essential hormones.”

Details of the four accepted abstracts are presented below:

  • Oral Presentation # ATTD19-0192: The Ultra-Rapid Insulin BioChaperone Lispro Bolused By Insulin Pump Shows Favourable Pharmacodynamics And Pharmacokinetics vs. Faster Aspart and Insulin Aspart

Presenting Author:          Dr. Grégory Meiffren

Session:                              Oral Presentations Session 4

Date and Time:                 Saturday, February 23, 2019 9:40 AM – 9:50 AM CET

Location:                            Hall M1

  • Oral Presentation # ATTD19-0201: BioChaperone Technology Enables The Development Of Pramlintide-Prandial Insulin Combinations

Presenting Author:          Dr. Grégory Meiffren

Session:                              Oral Presentations Session 2

Date and Time:                 Thursday, February 21, 2019 4:50 PM – 5:00 PM CET

Location:                            Hall 4

  • Poster # ATTD19-0198: BioChaperone Glucagon, A Stable Ready-To-Use Liquid Glucagon Formulation Enabled By Biochaperone Technology, Is Well Tolerated And Quickly Restores Euglycemia After Insulin-Induced Hypoglycemia

Presenting Author:          Aymeric Ranson

Session:                              PD05 E-Poster Discussion 05 (Station 4)

Date and Time:                 Friday, February 22, 2019 10:10 AM – 10:15 AM

Location:                            Exhibition Area

  • Poster # ATTD19-0194: BioChaperone Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects

Presenting Author:          Dr. Grégory Meiffren

Session:                              EPO2 E-Poster Viewing

Date and Time:                 Thursday, February 21, 2019 4:40 PM – 6:00 PM CET

Location:                            Exhibition Area

 

Date: February 20-23, 2019 in Berlin, Germany.

Place: CityCube Berlin
Messedamm 26
14055 Berlin

ATTD2019 WebSite